Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	20.95	-72.7	-135.35	-108.5	-73.96	-35.88
Depreciation & Amortization	8.33	8.12	6.22	3.75	2.13	0.54
Stock-Based Compensation	19.03	18.13	16.67	11.66	5.2	0.35
Other Adjustments	-3.02	-2.95	-3.81	2.76	0.98	7.68
Change in Receivables	-4.37	0.33	1.9	-0.19	-0.7	-
Changes in Accounts Payable	10.21	6.25	5.76	-0.74	6.59	3.44
Changes in Accrued Expenses	2.81	4.18	3.56	1.03	1.11	1.13
Changes in Unearned Revenue	92.66	83.38	50	-	-	-
Changes in Other Operating Activities	2.51	-2.75	11.25	-2.23	-0.71	-0.31
Operating Cash Flow	149.14	42	-43.8	-92.47	-59.36	-23.05
Capital Expenditures	-4.12	-3.99	-19.04	-12.91	-9.73	-3.39
Sale of Property, Plant & Equipment	-	-	0.06	0.11	0.08	-
Purchases of Investments	-290.98	-230.36	-103.15	-384.42	-	-
Proceeds from Sale of Investments	227.43	189.9	210.93	178	-	-
Investing Cash Flow	-67.66	-44.45	88.8	-219.22	-9.65	-3.39
Issuance of Common Stock	1.16	99.53	27.61	20.83	237.9	-
Net Common Stock Issued (Repurchased)	1.16	99.53	27.61	20.83	237.9	-
Issuance of Preferred Stock	-	-	-	-	143	60.5
Net Preferred Stock Issued (Repurchased)	-	-	-	-	143	60.5
Other Financing Activities	-	-0.64	-0.12	-0.36	-3.34	-0.44
Financing Cash Flow	1.34	98.89	27.49	20.47	377.56	60.06
Net Cash Flow	82.81	96.44	72.49	-291.22	308.55	33.62
Free Cash Flow	145.02	38.01	-62.84	-105.38	-69.1	-26.44
Free Cash Flow Growth	281.56%	-	-	-	-	-
FCF Margin	79.89%	50.26%	-	-	-	-
Free Cash Flow Per Share	1.76	0.51	-1.22	-2.23	-2.76	-17.43
Levered Free Cash Flow	133.35	22.5	-77.6	-119.61	-74.57	-34.48
Unlevered Free Cash Flow	120.53	11.11	-85.92	-123.5	-73.49	-26.61

Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q